Invesco Ltd. Has $15.11 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Invesco Ltd. decreased its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 17.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,907,246 shares of the company’s stock after selling 389,951 shares during the quarter. Invesco Ltd. owned 0.62% of Amneal Pharmaceuticals worth $15,105,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AMRX. Franklin Resources Inc. lifted its stake in Amneal Pharmaceuticals by 4.9% during the third quarter. Franklin Resources Inc. now owns 89,887 shares of the company’s stock worth $778,000 after purchasing an additional 4,178 shares during the period. Arizona State Retirement System grew its position in Amneal Pharmaceuticals by 13.6% in the fourth quarter. Arizona State Retirement System now owns 40,401 shares of the company’s stock valued at $320,000 after acquiring an additional 4,851 shares during the period. Alliancebernstein L.P. raised its stake in Amneal Pharmaceuticals by 2.5% during the fourth quarter. Alliancebernstein L.P. now owns 200,246 shares of the company’s stock worth $1,586,000 after acquiring an additional 4,927 shares in the last quarter. Globeflex Capital L P lifted its holdings in shares of Amneal Pharmaceuticals by 3.8% during the fourth quarter. Globeflex Capital L P now owns 144,439 shares of the company’s stock valued at $1,144,000 after acquiring an additional 5,245 shares during the period. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its holdings in shares of Amneal Pharmaceuticals by 13.6% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 46,240 shares of the company’s stock worth $366,000 after purchasing an additional 5,523 shares during the last quarter. 31.82% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on AMRX. Barclays boosted their price target on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, March 3rd. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the company from $9.00 to $12.00 in a report on Monday, February 24th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $10.80.

Amneal Pharmaceuticals Trading Up 2.5 %

Shares of AMRX stock opened at $7.36 on Monday. Amneal Pharmaceuticals, Inc. has a 1 year low of $5.18 and a 1 year high of $9.48. The firm’s 50 day moving average is $8.10 and its 200-day moving average is $8.24. The firm has a market capitalization of $2.28 billion, a price-to-earnings ratio of -10.82 and a beta of 1.06.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its earnings results on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. The firm had revenue of $730.52 million during the quarter, compared to analyst estimates of $708.21 million. During the same period last year, the business posted $0.14 earnings per share. On average, equities research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Insider Activity

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $8.14, for a total transaction of $651,200.00. Following the completion of the sale, the director now owns 1,888,886 shares of the company’s stock, valued at approximately $15,375,532.04. The trade was a 4.06 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the firm’s stock in a transaction on Friday, March 14th. The stock was sold at an average price of $8.35, for a total value of $41,750,000.00. Following the completion of the transaction, the insider now owns 48,578,209 shares in the company, valued at $405,628,045.15. This represents a 9.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 5,160,000 shares of company stock valued at $43,113,200. 26.56% of the stock is currently owned by insiders.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.